Association of N-Terminal Pro-Brain Natriuretic Peptide Concentration in Early Pregnancy With Development of Hypertensive Disorders of Pregnancy and Future Hypertension

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a observational study.

NT-proBNP concentration, measured using an electrochemiluminescence immunoassay from a first-trimester blood sample.

Who Took Part

According to the abstract, 4103 women were involved.

The age groups tagged for this paper are adults, both men and women.

A total of 4103 nulliparous women with complete data and no prepregnancy hypertension or diabetes who were treated at 8 clinical sites were included.

Women were followed up with for 2 to 7 years after pregnancy.

How the Study Was Run

In design terms this was a multicenter study.

More than one site took part, so the women came from several places.

This cohort study used data from the The Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be Heart Health Study, a prospective multicenter observational study.

Data were collected from October 2010 to October 2017, and data were analyzed from August 2020 to November 2021.

What Was Measured

NT-proBNP concentration, measured using an electrochemiluminescence immunoassay from a first-trimester blood sample.

PubMed files the paper under topics including Cardiovascular Diseases, Cohort Studies, Heart Diseases, Hypertension, Pregnancy-Induced, Natriuretic Peptide, Brain and Peptide Fragments.

What This Means in Plain Language

The paper is a multicenter study of BNP (Nesiritide) in 4103 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (JAMA cardiology), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.